Oncolytic herpes simplex virus (HSV) vectors have been used in early phase human clinical trials as a therapy for recurrent malignant glioblastoma. This treatment proved safe but limited improvements in patient survival were observed. The potency of these vectors might be enhanced by targeting vector infectivity to tumor cells. Glioma tumors often express a mutant form (vIII) of the epidermal growth factor receptor (EGFR) resulting in the presence of a novel epitope on the cell surface. This epitope is specifically recognized by a single-chain antibody designated MR1-1. HSV-1 infection involves initial binding to heparan sulfate (HS) on the cell surface mediated primarily by the viral envelope, glycoprotein C (gC). Here we joined the MR1-1 single-chain antibody (scFv) to the gC sequence deleted for the HS-binding domain as a means of targeting viral attachment to EGFRvIII on glial tumor cells. Virions bearing MR1-1-modified gC had fivefold increased infectivity for EGFRvIII-bearing human glioma U87 cells compared to mutant receptor-deficient cells. Further, MR1-1/EGFRvIII-mediated infection was more efficient for EGFRvIII-positive cells than was wild-type virus for either positive or negative cells. Sustained infection of EGFRvIII þ glioma cells by MR1-1-modified gC-bearing oncolytic virus, as compared to wild-type gC oncolytic virus, was also shown in subcutaneous tumors in vivo using firefly luciferase as a reporter of infection. These data show that HSV tropism can be manipulated so that virions recognize a cell-specific binding site with increased infectivity for the target cell. The retargeting of HSV infection to tumor cells should enhance vector specificity, tumor cell killing and vector safety.
Introduction
Malignant gliomas are the most common primary brain tumors and are almost universally fatal despite aggressive therapies, including surgery, radiotherapy and chemotherapy. 1 Patients with glioblastoma multiforme have a median survival of 12-18 months from initial diagnosis in spite of current treatments. Efforts to improve survival have included a variety of biologic therapies, such as viral vectors, monoclonal antibodies coupled to toxins and immunotherapy. [1] [2] [3] [4] [5] Several types of viral vectors derived from herpes simplex virus (HSV) are under development: attenuated replication-competent (replication-conditional) oncolytic recombinant virus, replication-deficient recombinant virus and amplicon vectors. 6 Thus far, oncolytic HSV has been used in early phase clinical trials for a variety of tumors, including glioblastoma multiforme. 1, [7] [8] [9] [10] [11] Genetically engineered oncolytic HSV, such as G207 and 1716, have been found to be relatively nontoxic for normal cells with some evidence of virus replication in tumors. These oncolytic viruses are designed to target cells based on rapid cell division or alterations in signal-transduction pathways that promote tumorigenesis, such as Ras activation. 12 They selectively replicate in dividing tumor cells so as to generate new vectors on-site and to 'leapfrog' some distance from the main tumor mass by replication and infection of tumor foci in the brain parenchyma. 13 Some progress has been made in targeting HSV infection selectively to tumor cells by using tumor-specific promoters to control viral genes critical to replication or by increasing infection of tumor cells. 14 Targeting of virion infection has the potential advantages of increasing infection of the appropriate target cell relative to normal cells, thereby increasing vector safety and potentially decreasing the effective vector dose. To accomplish targeted infection, virions must be modified to carry engineered ligands that bind specifically to tumor cells based on recognition of surface receptors. This depends on the identification of cell-specific surface receptor(s) that are more abundant on or unique to target cells and on modification of virions for recognition of these receptors without compromising infectivity. Successful targeting of vector infection to tumor cells has been achieved for other virus vectors, including adenovirus, 15, 16 adeno-associated virus 17 and retrovirus/lentivirus. 18 Infection by HSV involves initial binding of gC and gB envelope glycoproteins to heparan sulfate (HS) on the cell surface followed by binding of gD to natural receptors for HSV, HveA or HveC/nectin-1, and fusion between the virion envelope and cell plasma membrane. 19 Several attempts to alter the host range of HSV have been reported involving deletion of all of gC or its HS-binding domain (HSBD) and/or the HSBD of gB. 20, 21 Modified HSV-1 virions were targeted to cells expressing interleukin-13 receptors when the interleukin-13 ligand was introduced into gC or gD, 22 and virions with the his-tag preferentially infected cells expressing a pseudo-his-tag receptor. 23 HSV-1 binding has also been altered by the introduction of ligands into gC for the pre-SI peptide from hepatitis B virus that targets hepatocytes 21 and erythropoietin that targets its cognate receptor implicated in angiogenesis. 24 An alternative approach to introducing novel ligands into viral glycoproteins for targeted HSV entry involves the development of soluble adapter molecules designed to mediate both cell-specific-binding and the gD-dependent fusion. The V domain of HveC, which binds gD, was fused to a single-chain antibody (scFv) to the epidermal growth factor receptor (EGFR) in an effort to target EGFR-bearing cells. 25 These reports show the feasibility of modifying the HSV virion to achieve specific cell targeting.
For cancer therapy, cell-surface receptors for virus targeting should include ones enriched or mutated on tumor cells. A specific mutant form of EGFR, EGFRvIII, is highly expressed on many glioblastomas, breast carcinomas and other tumors, 26 and is associated with increased invasiveness and growth rate of tumors. 27 Several antibodies have been described that are specific to EGFRvIII and do not cross-react with wild-type EGFR. One of these, mutant receptor 1 (MR1), was isolated by the Bigner Laboratory from an scFv phage display library by panning with successively decreasing amounts of EGFRvIII mutant-specific peptide. 4 By mutagenesis and selection using a phage display library a variant of MR1 was identified, MR1-1, which has an approximately 15-fold higher binding affinity to the EGFRvIII extracellular domain as compared to MR1. 28 This group also generated a mutated form of MR1-1, MRB, with no affinity for EGFRvIII.
Here we report the generation of an oncolytic HSV vector targeted to glial tumor cells expressing EGFRvIII. The coding sequence for scFv MR1-1 was fused in-frame with gC lacking the HSBD (gCD). This recombinant gC molecule was designed to replace native HS binding with EGFRvIII-specific binding. Virions containing only MR1-1-gCD (and no wild-type gC) were shown to infect EGFRvIII-expressing glioma cells with a fivefold increase in efficiency as compared to wild-type gC virions in culture. Injection of MR1-1-gCD and gC wild-type virions encoding firefly luciferase (Fluc) into subcutaneous human glioma U87 tumors expressing EGFRvIII in nude mice revealed more sustained infection by MR1-1-gCD virions over the first week after infection, as compared to gC wild-type virions. These data show that HSV tropism can be shifted to recognition of tumor-specific receptors with apparent enhancement tumor-specific vector replication.
Materials and methods
Cell culture Vero 2-2 (2-2) cells stably transfected with the HSV gene for ICP27 (from Dr Rozanne Sandri-Goldin, University of California at Irvine, CA), 29 U87MG cells (from the American Type Culture Collection) and U87MGEGFR (here termed U87DEGFR, expressing the mutant EGFRvIII receptor from Dr Web Cavenee, Ludwig Cancer Institute, CA) were maintained in Dulbecco's modified Eagle's medium growth medium supplemented with 200 mM L-glutamine (Invitrogen, Carlsbad, CA), 100 U ml À1 penicillin and 100 g ml À1 streptomycin (Sigma, St Louis, MO) and 10% fetal bovine serum (Sigma). The U87DEGFR cell line was generated by transfecting U87MG cells with an expression cassette for EGFRvIII and Neo R30 and expresses 4-13 Â 10 5 EGFRvIII receptors per cell in culture. 31 Expression of EGFRvIII on U87DEGFR and lack of expression on U87 cells was confirmed by SDS-polyacrylamide gel (PAGE) and western blot analysis of cell lysates using L8A4 antibody (kindly provided by Dr Darrell Bigner, Duke University Medical Center) (data not shown). Geneticin (G418; Invitrogen) was added to 2-2 and U87DEGFR cells at 400 g ml À1 to select for continued transgene expression.
Helper virus stock
The HSV recombinant viruses used in this study were hrR3 (ICP6-minus, lacZ þ mutant from Dr Sandra Weller, University of Connecticut) 32 and gCD2-3 (gCminus, lacZ þ ; from Dr Curtis Brandt, University of Wisconsin), 33 both derivatives of HSV strain KOS.
hrR3 and gCD2-3 stocks were prepared by infecting 2-2 cells at a multiplicity of infection (MOI) of 1 transducing unit (tu) per cell. Cells and medium were harvested after approximately 16-24 h when the cells displayed 100% cytopathic effect and subjected to three cycles of freezethawing (alternating between À80 and 37 1C baths). The virus were then separated from cell debris by low-speed centrifugation (500 g Â 10 min at room temperature) and the supernatant concentrated by centrifugation at 72 000 g for 3 h at 4 1C through a 25% sucrose cushion. 34 Virus stocks were resuspended in phosphate-buffered saline (PBS), pH 7.4, and aliquoted into 2 ml cryogenic tubes (Corning Incorporated (Corning), NY), stored at À80 1C and titered by transduction assay. This virus was titered either as tu (lacZ þ cells; see below) or plaque-forming units (PFU) on Vero cells. 23 Titering by transduction 2-2 Cells (1.5 Â 10 6 per well in six-well plates) were infected in a total volume of 1 ml Dulbecco's modified Eagle's medium with dilutions of virus stocks (10 2 -10 11 ) in duplicate. After incubation at 37 1C for 2 h, the viral solution was aspirated, the cells washed twice with PBS and replaced with normal growth medium. For lacZ þ virus, cells were fixed 24 h later in 4% paraformaldehyde (EMS, Fort Washington, PA) in PBS for 10 min at room temperature. Cells were washed twice with PBS and stained with X-galactosidase (X-gal) solution (pH 7.4) overnight at 37 1C. 35 For amplicon vectors, cells were visualized for expression of enhanced green fluorescent protein (GFP) for CONG vectors or red fluorescent protein (RFP) for HRCFluc vectors 24 h after infection by fluorescence microscopy.
Amplicon construction
The full-length HSV-1 gC gene with its own promoter was subcloned between the PstI and HindIII sites in an amplicon plasmid (pCONG) bearing an expression cassettes for GFP and neomycin resistance (Neo R ) (from pcDNA3.1 (À); Invitrogen) inserted into a unique XhoI site downstream of the gC gene. 36 The HSBD of gC was deleted by digestion with AscI and EcoNI, corresponding to removal of amino acids 33-174 (423 bp), and replaced with in-frame sequences for MR1-1, the single-chain antibody able to bind specifically and with high affinity to the EGFRvIII or with a mutated form of that antibody, MRB, that no longer binds to the receptor (from Dr Bigner). MR1-1 and MRB sequences were amplified by PCR from plasmids pHRST MR1-1 and PHRST MRB 28 using the following primers: 5 0 primer: 5 0 -CATGGCGCGCCCGATGGACTGGATTTGGCGC-3 0 and 3 0 primer: 5 0 -CAGGACCTCCTCTAGGTCTAGT TTTTCAAGCTTGGT-3 0 .
The firefly luciferase cDNA (Promega, Madison, WI) was subcloned into the NheI and XbaI restriction sites of the amplicon plasmid pHRCX, derived from pHCGX 37 with the eGFP expression cassette replaced by one for Discosoma RFP (DsRed2; Clontech, Mountain View, CA). 38 
Generation and titering of amplicon vector and helper virus
To generate vector stocks, we transfected amplicon plasmids, pCONG, pCONG-MR1-1-gCD, pCONG-MRB-gCD and pHRCFluc separately into 2-2 cells (6 Â 10 6 per 100 mm plate) using Lipofectamine (Invitrogen) according to manufacturer's protocol. At 24 h after transfection, the cell monolayers were infected at an MOI of 1 with gCD2-3 virus. Virus was harvested when 100% cytopathic effect was evident and concentrated as described above. Titers of amplicon vector and helper virus were determined by transduction assay counting GFP-or RFP-positive cells for amplicon vectors and lacZ þ cells for helper viruses. Typically titers were 1-5 Â 10 9 tu per ml for helper virus and 1-10 Â 10 7 tu per ml for amplicon vectors. For in vivo experiments, vector stocks were generated that contained gCD2-3 helper virus and two amplicon vectors: HRCFlucexpressing RFP/Fluc and either the CONG-gC encoding wild-type gC or CONG-MR1-1-gCD (or CONG-MRB-gCD) encoding a recombinant protein including scFv MR1-1 (or MRB) and gC deleted for HSBD. Virus titers for stocks used in in vivo experiments were as follows: CONG-MR1-1-gCD/HRCFluc/gCD2-3 contained CONG amplicon (GFP þ ) ¼ 5 Â 10 7 tu per ml, HRCFluc amplicon (RFP þ ) ¼ 1 Â 10 8 tu per ml and gCD2-3 virus (lacZ þ ) ¼ 3.3 Â 10 9 tu per ml; and CONG-gC/HRCFluc/ gCD2-3 contained CONG amplicon (GFP þ ) ¼ 1.7 Â 10 7 tu per ml, HRCFluc amplicon (RFP þ ) 5 Â 10 8 tu per ml and gCD2-3 virus (lacZ þ ) ¼ 5 Â 10 9 tu per ml.
Western blot analysis of modified gC in virions Amplicon vector and virus stocks were prepared as above. Stocks were spun at 1500 r.p.m. in IECCentra-8R tabletop centrifuge for 5 min and supernatants (approximately 30 ml) were layered on sucrose gradients consisting of 3 ml 10% sucrose, 7 ml 30% sucrose and 7 ml of 60% sucrose in PBS and centrifuged at 25 000 r.p.m. in an SW28 rotor at 4 1C for 1 h. Pelleted virus was resuspended in PBS and centrifuged repeated. Then virion pellets (equivalent to about 10 7 PFU each) were resuspended in lysis buffer (50 mM Tris (pH 8), 150 mM NaCl, 0.02% Na azide, 0.1% SDS, 1% Triton X100, 1 Â Protease Inhibitor Cocktail (Roche, Indianapolis, IN)). Half of samples were treated with N-glycosidase F according to manufacturer's instructions (New England Biolabs, Beverly, MA), which cleave between the innermost GlcNAc and asparagine residues of high mannose, hybrid and complex oligosaccharides from N-linked glycoproteins. Untreated and glycosidase-treated samples were resolved by electrophoresis in a 12% SDS-PAGE, transferred to a nitrocellulose membrane and immunoblotted with antibodies specific for gC (1:10000; rabbit 47 polyclonal antibody; kindly provided by Dr GH Cohen and Dr RJ Eisenberg, University of Pennsylvania), 39 gD (1:1000 mouse monoclonal; Goodwin Labs, Plantation, FL) and VP16 (1:500 mouse monoclonal LP1, kindly provided by Dr Tony Minson, Division of Virology, Department of Pathology, Cambridge University, UK) in 2% milk, 1 Â TBS 0.05% Tween 20 (TBS-T). The membranes were then washed three times with TBS-T and incubated for 1 h at room temperature with anti-mouse or anti-rabbit horseradish peroxidase-conjugated antibody (Sigma) in 5% milk TBS-T solution. After incubation, the blots were washed again and antibody signal revealed by enhanced chemiluminescence (Pierce, Rockford, IL).
Binding and penetration assay
Monolayers of confluent U87 and U87DEGFR cells (1.5 Â 10 6 per well in six-well plates) were incubated at 4 1C for 30 min, washed twice with cold PBS and incubated with different virus stocks (gCD2-3 (gC-minus), CONG-MR1-1-gCD, gC-minus, CONG-MRB-gCD, CONG-gC þ gC-minus and hrR3) at identical titers (10 5 tu lacZ per well, six-well plate) in triplicate. The viruses
Targeting HSV-1 virions to EGFRvIII P Grandi et al were allowed to bind for 60 min at 4 1C after which the unbound virus was removed by washing the cells 3 Â with cold PBS. Cells were then shifted to 37 1C to allow virus penetration. At 24 h after infection, cells were stained for lacZ to determine the number of cells infected.
In vivo studies Athymic nude mice (nu/nu; 8 weeks old, females; Massachusetts General Hospital Colony) were implanted with U87DEGFR tumor cells (5 Â 10 6 in 100 ml Dulbecco's modified Eagle's medium) subcutaneously into one flank of each mouse. Two weeks later tumors were injected with 5 Â 10 5 tu (HRCFluc) vector stocks in 5 in l using MR1-1-gCD CONG þ HRCFluc þ gCD2-3 or gC CONG þ HRCFluc þ gCD2-3 stocks. At 24 h, 48 h and 1 week after vector injection mice were imaged for Fluc activity by intraperitoneal injection of D-luciferin (4.5 mg per animal in 150 l saline) and photon counts recorded 10 min later using a cryogenically cooled high-efficiency change-coupled device camera system (Roper Scientific, Trenton, NJ). Post-processing and visualization was performed as described. 40 
Results
Constructs and virus used to generate and monitor targeted virions gC fusion proteins were generated in which full-length scFv sequences for antibodies with varying affinity for EGFRvIII were used to replace amino acids 33-174 of wild-type gC, thus eliminating the HSBD. 41 Antibody sequences for the extracellular EGFRvIII domain included those for the very high affinity scFv, MR1-1, and the mutated scFv, MRB with little-to-no affinity 4, 28 (kindly provided by Dr Darell Bigner, Duke University Medical Center). Expression constructs for MR1-1-gCD, MRB-gCD and gCD, all under the gC promoter, were inserted in the pCONG amplicon that also contains an expression cassette for GFP to monitor amplicon vector infection 36, 23, 42 (Figure 1 ). To create stocks in which virions carried only modified gC in their envelope, we transfected cells with one of the scFv amplicons and then infected them with a mutant HSV, gCD2-3, in which the gC gene is deleted and replaced with a lacZ expression cassette. 33 Controls included virions generated by transfection with pCONG amplicon carrying the wild-type gC gene and infection with gCD2-3, or a virus stock of the HSV mutant, hrR3, which encodes wild-type gC and has a lacZ expression cassette in place of the gene encoding the large subunit of ribonucleotide reductase. 32 
Characterization of targeted virions
To analyze incorporation of modified gC into virions, we purified virus stocks including hrR3 virus carrying wildtype gC, gCD2-3 virus lacking gC (gC-minus) and gCD2-3 virus packaged in the presence of the MR1-1-gCD amplicon by banding on sucrose gradients to remove cellular proteins. Then the equivalent of 10 7 PFU per stock was left untreated or deglycosylated with endoglycosidase F and resolved by SDS-PAGE with western blotting carried out using antibodies to envelope proteins, gC and gD, and to the tegument protein, VP16 (Figure 2 ). Wild-type gC contains both N-and O-linked glycosyl residues, with only the N-linked side chains being sensitive to endoglycosidase F. The N-glycosidase-treated gC wild-type virions showed a reduction in molecular weight with different sized bands representing the extent of remaining O-glycosylation. No gC immunoreactive band was seen for gCD2-3 virus. MR1-1-gCD virus revealed one gC band of 64 kDa, which is consistent with the predicted single (glycosylation) event based on its Targeting HSV-1 virions to EGFRvIII P Grandi et al sequence (Figure 2a ). Staining with antibodies to gD revealed a single band resulting from deglycosylation (Figure 2b) . Interestingly, there appeared to be somewhat more gD per infectious virion for MR1-1-gCD, and somewhat less for gC-minus virus, as compared to the wild-type virus for the same PFU. VP16 was also substantially increased in the MR1-1-gCD virions as compared to wild-type and gCD2-3 virions (Figure 2c) . Thus, the relative ratio of gD in infectious virions appeared to vary with the presence and type of gC.
In the absence of gC, infectious virions had reduced levels of gD as compared to wild-type virions, whereas in the presence of modified gC there was an apparent increase in gD. Because a similar pattern of altered VP16 levels was observed, it is likely that these changes reflect an increase in particle to PFU ratios rather than gC-dependent alterations in gD incorporation into the vector envelope.
Binding and infection efficiency of MR1-1-modified virions for glioma cells with and without EGFRvIII receptors
To evaluate the differential infectivity of glioma cells expressing and not expressing EGFRvIII receptors, we incubated U87 and U87DEGFR (stably transduced with an expression cassette for EGFRvIII) cells with vectors for 60 min at 4 1C, then washed and incubated them at 37 1C for 24 h and evaluated transgene expression (lacZ) (Figure 3 ). Infections used similar transducing units (tu) (lacZ) of gC-minus (gCD2-3), and gC-minus virus packaged during transfection with MR1-1-gCD, MRB-gCD or gC amplicon DNA, as well as wild-type gC (hrR3). At low MOI (0.015 PFU per cell) virions with gC bearing the high-affinity antibody, MR1-1, showed increased infectivity (45-fold) for U87DEGFR cells as compared to U87 cells (Figure 3 ). This phenomenon was less pronounced at higher MOI (0.15), but still showed a twofold increase for MR1-1-gCD infection of U87DEGFR versus U87 cells (data not shown). Remarkably, the infectivity of the MR1-1-gCD-modified virions was greater than that of wild-type virions for glioma cells expressing EGFRvIII by about sixfold at MOI ¼ 0.015 and a little less than twofold at MOI ¼ 0.15 (data not shown). No significant difference in binding/infection between U87 and U87DEGFR cells was seen for any of the other vector stocks, including gC-minus, MRB-gCD and hrR3. Virions lacking gC had similar infectivity to those with wild-type gC at MOI ¼ 0.015. Further, virions prepared by transfection with an amplicon encoding gC Targeting HSV-1 virions to EGFRvIII P Grandi et al and infection with gC-minus virus, behaved like a gC wild-type virus (hrR3). These results indicate that MR1-1 in the context of gC deleted for the HSBD can increase infectivity for cells expressing the EGFRvIII, even beyond that of wild-type virus.
Relative efficiency of targeting of gC and MR1-1-gCDmodified virions to U87DEGFR tumors in vivo
To monitor infection of tumors in vivo by bioluminescence imaging, we generated amplicons that encoded Fluc under the CMV promoter, termed HRCFluc. This amplicon was then co-transfected with pCONG amplicons (gC or MR1-1-gCD) and packaged with gC-minus helper virus. U87DEGFR tumor cells (5 Â 10 5 ) were implanted subcutaneously in nude mice and given 2 weeks to form small unilateral tumor. Two vector stocks were compared both generated using HRCFluc amplicon and gCD2-3 virus-one with MR1-1-gCD CONG and the other with gC CONG amplicon transfection. Tumors were injected directly with virus stocks normalized to 5 Â 10 5 tu HRCFluc amplicon vector (containing 1.5-2.5 Â 10 7 gCminus helper virus and about 2 Â 10 4 tu CONG amplicon vectors). Bioluminescence of tumors was tracked over a 1-week period (Figure 4 ). At 24 h after infection, a very strong bioluminescence signal was seen in all tumors. At 48 h after vector injection, this diminished, but a robust signal was still seen in tumors infected with both vector types. After 1 week, however, a markedly stronger bioluminescence signal was seen in tumors infected with virions incorporating MR1-1-gCD versus gC. Because Fluc is expressed by the amplicon vector and equal numbers of tu were introduced into the tumor for amplicons containing either gC or MR1-1-gCD, the MR1-1-gCD vector provided a higher level of initial infection than the gC vector. This signal may have been amplified by possible intratumoral replication and packag ing of the HRCFluc amplicon vector supported by gCD2-3 viral replication. This in vivo experiment supports the ability of MR1-1-gCD virions to increase infectivity of tumor cells expressing EGFRvIII, as compared to gC virions.
Discussion
This study shows that infectivity of HSV virions can be directed to specific cell-surface receptors by fusion of receptor-specific scFv antibody sequences to the N terminus of the gC envelope glycoprotein, lacking the HSBD. In this case MR1-1 antibody sequences were used, which bind with very high affinity to mutant EGFR (EGFRvIII) found on many tumor cells. 4 Infectivity of MR1-1-gCD virions was increased over fivefold for human glioblastoma cells expressing this mutant receptor as compared to virions bearing wild-type gC at low MOI This low MOI mimics the relatively low ratio of vector to tumor cells expected in therapeutic paradigms in vivo. Further, the targeted virions achieved markedly higher infectivity for cells expressing EGFRvIII as compared to wild-type virus, indicating that the infection efficiency of HSV can be selectively increased for specific cell types above natural levels of infectivity by genetic manipulation of the virion surface. This targeted virion design was also found to be effective in prolonging expression of a luciferase reporter gene in subcutaneous Targeting HSV-1 virions to EGFRvIII P Grandi et al glioma tumors following direct injection of vector incorporating MR1-1-gCD fusion protein as compared to gC. Further studies are in progress to increase the specificity of this HSV oncolytic vector by introducing the MR1-1 binding ligand into additional HSV glycoprotein envelope molecules. Similar vector retargeting studies were recently reported by Paraskevakou et al. 43 using replication competent measles virus. They generated a retargeted virus by recombining a single-chain antibody specific for EGFR into the virus hemagglutinin deleted for the natural CD46 or SLAM receptor recognition sites. The measles vector differed from our MR1-1-gCD HSV vector in as much HSV was shown to recognize with enhanced binding activity only the mutant form of the EGFR receptor found on glioblastoma cells and infection was more efficient than wild-type HSV. The measles vector, however, bound both the mutant and wild-type form of EGFR. This difference may impart a measure of enhanced safety for the HSV recombinant virus because wild-type EGFR is expressed in normal brain cells. 44 To evaluate infection efficiency of different virions, we produced amplicon vectors expressing gC or modified gC together with replication competent helper virus that was gC deficient. In this way gC or modified gC was incorporated into the envelope of both the amplicon and helper virus virions in the same stock. This strategy relies on plasmid-based amplicons to supply and screen targeted glycoproteins and avoids the more laborintensive process of generating recombinant viruses encoding various modifications of envelope proteins. This same approach could be used to modify gB and/or gC using gC-minus and gB-minus virus that are replication competent. By using amplicons to produce modified glycoproteins one simplifies constructions by plasmidbased recombination and transfection of cells. Thus, by infecting amplicon-transfected cells with replication competent virus deleted or mutated in viral glycoprotein genes, modifications that enhance selected infection can be readily screened. This screening is further simplified by monitoring infection using fluorescent or lacZ reporter genes in culture or bioluminescent enzymes in vivo incorporated into amplicon vectors or virus. 40, [45] [46] [47] This strategy should also be effective in combination with an oncolytic virus vector with wild-type gC, as the overexpression of the targeted form of gC can result in greater levels of modified gC incorporated into virions than wild-type gC. For example, we previously observed that infection by the oncolytic virus, hrR3 along with transfection of an amplicon plasmid encoding his-tagged gCD resulted in enveloped virus particles that contained a high ratio of gC-his-tag compared to wild-type gC. 23 Treatment of engineered target cells bearing a pseudo-his-tag receptor with anti-his-tag antibodies reduced the efficiency of infection and plaque formation by these his-tagged virions by 1-2 logs.
HSV recombinant and amplicon vectors have been used separately and in combination for gene therapy for brain tumors. 6, 48 Therapeutic genes can be incorporated into both replicative recombinant virus and amplicon vectors and co-produced, allowing the use of amplicons for both virion targeting and for expression of other genes that may increase tumor killing and oncolytic vector effectiveness. [49] [50] [51] This study shows the ability to increase infectivity of HSV virions for specific cell types by modification of envelope glycoproteins. In this case, a high-affinity antibody expressed on the virion to the mutant EGFR present on glioma cells was able to increase infection efficiency in culture by fivefold at low MOI and to sustain transgene expression in tumors in vivo. The enhancement of targeted infection at lower MOI corresponds to decreasing concentrations of oncolytic virus during propagation and spread within the tumor in vivo. Vector targeting also provides an added safety advantage in that targeted vectors can selectively infect tumor cells as compared to normal cells, thus reducing toxicity to normal cells. Given that glioblastomas are heterogeneous and continually undergoing changes in tumor characteristics and cell-surface markers, virion predicted to target different tumor cell phenotypes might be achieved by tailoring the specificity of infection to different tumor surface receptors.
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